Sorafenib in radioactive iodine-refractory, locally advanced or metastatic diff erentiated thyroid cancer: A randomised, double-blind, phase 3 trial

The Lancet

Volumn 384, Issue 9940, 2014, Pages 319-328

  Brose, Marcia S ^a   Nutting, Christopher M ^b   Jarzab, Barbara ^c   Elisei, Rossella ^d   Siena, Salvatore ^e   Bastholt, Lars ^f   De La Fouchardiere, Christelle ^g   Pacini, Furio ^h   Paschke, Ralf ⁱ   Shong, Young Kee ^j   Sherman, Steven I ^k   Smit, Johannes W A ^l   Chung, John ^m   Kappeler, Christian ⁿ   Peña, Carol ^m   Molnár, István ^m   Schlumberger, Martin J ^o  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d UNIVERSITY OF PISA   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g HOSPICES CIVILS DE LYON   (France)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

^j Asan Medical Center   (South Korea)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m BAYER CORPORATION   (United States)

ⁿ BAYER PHARMA AG   (Germany)

^o UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; PLACEBO; RADIOACTIVE IODINE; RAS PROTEIN; SORAFENIB; THYROGLOBULIN; THYROTROPIN; IODINE 131;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BACKACHE; CANCER PROGNOSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DESQUAMATION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; THYROGLOBULIN BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADVANCED CANCER; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DRUG ERUPTION; INTENTION TO TREAT ANALYSIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA METASTASIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904855170     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60421-9     Document Type: Article

References (30)

1. Cooper DS, Doherty GM, Haugen BR, et al, and the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and diff erentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid carcinoma v2. 2013. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp (accessed April 1, 2013).
3. Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003; 197: 191-97.
4. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-99.
5. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014; published online Jan 30. http://dx.doi.org/10.1016/S2213- 8587(13)70215-8.
6. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-99.
7. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-49.
8. Xing M. Prognosticutility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 321: 86-93.
9. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: The University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; 139: 1164-70.
10. Xing M, Haugen BR, Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer. Lancet 2013; 381: 1058-69.
11. Klein M, Vignaud J-M, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 656-58.
12. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the effi cacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol 2011; 165: 315-22.
13. Bible KC, Suman VJ, Molina JR, et al, and the Endocrine Malignancies Disease Oriented Group, the Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic diff erentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11: 962-72.
14. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16: 5260-68.
15. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26: 4708-13.
16. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-19.
17. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial eff ects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161: 923-31.
18. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-84.
19. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic diff erentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905.
20. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory diff erentiated thyroid carcinoma: Final results of a phase II trial. Eur J Endocrinol 2012; 167: 643-50.
21. Sherman SI, Wirth LJ, Droz J-P, et al, and the Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive diff erentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
22. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical, safety, and economic evidence in radioactive iodinerefractory differentiated thyroid cancer: A systematic literature review. Thyroid 2013; 23: 392-407.
23. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
24. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-34.
25. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: A double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011; 11: 349.
26. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW, Smit JW. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012; 23: 10-18.
27. Marotta V, Ramundo V, Camera L, et al. Sorafenib in advanced iodine-refractory diff erentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol 2013; 78: 760-67.
28. Escudier B, Eisen T, Stadler WM, et al, and the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
29. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Fi nal effi cacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-18.
30. Llovet JM, Ricci S, Mazzaferro V, et al, and the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.